J. Alexander Bodkin, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Selegiline | 6 | 2012 | 31 | 1.050 |
Why?
|
| Psychotropic Drugs | 2 | 2020 | 893 | 0.940 |
Why?
|
| Monoamine Oxidase Inhibitors | 5 | 2012 | 158 | 0.870 |
Why?
|
| Affective Disorders, Psychotic | 2 | 2019 | 191 | 0.760 |
Why?
|
| Antidepressive Agents | 9 | 2019 | 2838 | 0.710 |
Why?
|
| Glycine Dehydrogenase (Decarboxylating) | 1 | 2019 | 15 | 0.700 |
Why?
|
| Glycine Agents | 1 | 2019 | 17 | 0.700 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2020 | 336 | 0.610 |
Why?
|
| Job Satisfaction | 1 | 2020 | 535 | 0.560 |
Why?
|
| Depressive Disorder, Major | 8 | 2019 | 4628 | 0.560 |
Why?
|
| Glycine | 1 | 2019 | 671 | 0.530 |
Why?
|
| Psychiatry | 4 | 2020 | 1695 | 0.500 |
Why?
|
| Psychotic Disorders | 7 | 2019 | 3040 | 0.480 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 895 | 0.460 |
Why?
|
| Managed Care Programs | 1 | 2019 | 949 | 0.460 |
Why?
|
| Famous Persons | 1 | 2012 | 108 | 0.390 |
Why?
|
| Buprenorphine | 4 | 2019 | 640 | 0.340 |
Why?
|
| Thiophenes | 2 | 2011 | 590 | 0.340 |
Why?
|
| Anxiety Disorders | 5 | 2011 | 2684 | 0.320 |
Why?
|
| Amino Sugars | 1 | 2008 | 40 | 0.320 |
Why?
|
| Mental Health Services | 1 | 2019 | 1643 | 0.310 |
Why?
|
| Gift Giving | 1 | 2007 | 80 | 0.280 |
Why?
|
| Naltrexone | 2 | 2019 | 307 | 0.260 |
Why?
|
| Schizophrenia | 7 | 2017 | 6874 | 0.240 |
Why?
|
| Social Class | 1 | 2012 | 1995 | 0.220 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 3667 | 0.210 |
Why?
|
| Double-Blind Method | 8 | 2019 | 12017 | 0.210 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 2211 | 0.200 |
Why?
|
| Life Change Events | 1 | 2006 | 937 | 0.200 |
Why?
|
| Fees, Pharmaceutical | 1 | 2020 | 64 | 0.190 |
Why?
|
| Insurance, Psychiatric | 1 | 2020 | 69 | 0.180 |
Why?
|
| Drug Therapy, Combination | 5 | 2019 | 6483 | 0.170 |
Why?
|
| Depressive Disorder | 4 | 2012 | 3748 | 0.170 |
Why?
|
| Antipsychotic Agents | 2 | 2005 | 3058 | 0.150 |
Why?
|
| Patient Dropouts | 2 | 2012 | 421 | 0.150 |
Why?
|
| Videotape Recording | 1 | 1998 | 350 | 0.150 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2019 | 6030 | 0.140 |
Why?
|
| Adult | 25 | 2020 | 213712 | 0.140 |
Why?
|
| Biological Psychiatry | 1 | 1995 | 25 | 0.140 |
Why?
|
| Ambulatory Care | 2 | 2005 | 2706 | 0.130 |
Why?
|
| Administration, Cutaneous | 3 | 2012 | 711 | 0.130 |
Why?
|
| Endophenotypes | 1 | 2017 | 250 | 0.130 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 2217 | 0.130 |
Why?
|
| Bupropion | 1 | 1997 | 303 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2019 | 1791 | 0.130 |
Why?
|
| Random Allocation | 1 | 2019 | 2425 | 0.120 |
Why?
|
| Secondary Prevention | 3 | 2011 | 1520 | 0.120 |
Why?
|
| Thinking | 1 | 2017 | 319 | 0.120 |
Why?
|
| Physician-Patient Relations | 1 | 2007 | 3215 | 0.110 |
Why?
|
| Mental Disorders | 2 | 2012 | 6587 | 0.110 |
Why?
|
| Male | 29 | 2020 | 349538 | 0.110 |
Why?
|
| Psychoanalytic Therapy | 2 | 2007 | 230 | 0.110 |
Why?
|
| Tyramine | 1 | 2012 | 52 | 0.110 |
Why?
|
| Clonazepam | 2 | 1990 | 136 | 0.110 |
Why?
|
| Food-Drug Interactions | 1 | 2012 | 27 | 0.110 |
Why?
|
| Craniofacial Abnormalities | 1 | 2015 | 315 | 0.110 |
Why?
|
| Female | 26 | 2020 | 379592 | 0.100 |
Why?
|
| Dissent and Disputes | 1 | 2012 | 138 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2006 | 4248 | 0.100 |
Why?
|
| Hospitals, Psychiatric | 1 | 2012 | 332 | 0.090 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1940 | 0.090 |
Why?
|
| Middle Aged | 21 | 2020 | 213127 | 0.090 |
Why?
|
| Visual Perception | 1 | 1998 | 1417 | 0.090 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2006 | 1953 | 0.090 |
Why?
|
| Panic | 1 | 1989 | 106 | 0.090 |
Why?
|
| Fetal Development | 1 | 2015 | 767 | 0.080 |
Why?
|
| Schizophrenic Psychology | 4 | 2009 | 1677 | 0.080 |
Why?
|
| Patient Compliance | 2 | 2012 | 2680 | 0.080 |
Why?
|
| Bipolar Disorder | 2 | 2017 | 5024 | 0.080 |
Why?
|
| Humans | 33 | 2020 | 742088 | 0.080 |
Why?
|
| Hydroxylation | 1 | 2008 | 141 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2019 | 62966 | 0.080 |
Why?
|
| Sertraline | 2 | 2000 | 206 | 0.080 |
Why?
|
| Anti-Anxiety Agents | 1 | 1990 | 390 | 0.080 |
Why?
|
| Placebos | 2 | 2005 | 1677 | 0.080 |
Why?
|
| Health Expenditures | 1 | 2020 | 2346 | 0.080 |
Why?
|
| Symbolism | 1 | 2007 | 34 | 0.070 |
Why?
|
| Ethics Committees | 1 | 2007 | 53 | 0.070 |
Why?
|
| Stereoisomerism | 1 | 2008 | 625 | 0.070 |
Why?
|
| Esters | 1 | 2008 | 210 | 0.070 |
Why?
|
| Panic Disorder | 2 | 2004 | 616 | 0.070 |
Why?
|
| Trichosporon | 1 | 2006 | 8 | 0.070 |
Why?
|
| Medicaid | 1 | 2020 | 2716 | 0.070 |
Why?
|
| Logistic Models | 2 | 2020 | 13403 | 0.070 |
Why?
|
| Molecular Conformation | 1 | 2008 | 563 | 0.070 |
Why?
|
| Patient Care Planning | 1 | 2012 | 921 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 12242 | 0.070 |
Why?
|
| Psychotherapy | 1 | 1995 | 1644 | 0.070 |
Why?
|
| Massachusetts | 1 | 2019 | 8662 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2012 | 2615 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2012 | 950 | 0.070 |
Why?
|
| Candida | 1 | 2006 | 172 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1503 | 0.060 |
Why?
|
| Family Health | 1 | 2009 | 1282 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2008 | 1802 | 0.060 |
Why?
|
| Hypochondriasis | 1 | 2004 | 92 | 0.060 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 507 | 0.060 |
Why?
|
| Time Factors | 3 | 2019 | 40054 | 0.060 |
Why?
|
| Candida albicans | 1 | 2006 | 394 | 0.060 |
Why?
|
| United States | 4 | 2020 | 69693 | 0.060 |
Why?
|
| Professional-Family Relations | 1 | 2007 | 481 | 0.050 |
Why?
|
| Aged | 9 | 2020 | 162944 | 0.050 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2002 | 1442 | 0.050 |
Why?
|
| Asperger Syndrome | 1 | 2002 | 63 | 0.050 |
Why?
|
| Conflict of Interest | 1 | 2007 | 542 | 0.050 |
Why?
|
| Antifungal Agents | 1 | 2006 | 729 | 0.050 |
Why?
|
| Alcoholism | 1 | 2012 | 1904 | 0.050 |
Why?
|
| Ethics, Medical | 1 | 2007 | 791 | 0.050 |
Why?
|
| Comorbidity | 2 | 2015 | 10372 | 0.050 |
Why?
|
| Cognition | 1 | 1998 | 6722 | 0.050 |
Why?
|
| Ligands | 1 | 2008 | 3293 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2012 | 2527 | 0.050 |
Why?
|
| Fear | 1 | 1989 | 1436 | 0.050 |
Why?
|
| Fluoxetine | 2 | 1997 | 749 | 0.040 |
Why?
|
| Personality Inventory | 1 | 2002 | 1026 | 0.040 |
Why?
|
| Psychoanalytic Interpretation | 1 | 1998 | 57 | 0.040 |
Why?
|
| Adolescent | 4 | 2016 | 85649 | 0.040 |
Why?
|
| Repression, Psychology | 1 | 1998 | 44 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2008 | 5454 | 0.040 |
Why?
|
| 1-Naphthylamine | 1 | 1997 | 49 | 0.040 |
Why?
|
| Fluvoxamine | 1 | 1997 | 74 | 0.040 |
Why?
|
| Dysthymic Disorder | 1 | 1997 | 74 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2005 | 3913 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2012 | 4229 | 0.040 |
Why?
|
| Dissociative Disorders | 1 | 1999 | 231 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2006 | 6534 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 4250 | 0.030 |
Why?
|
| Basal Ganglia Diseases | 1 | 1996 | 149 | 0.030 |
Why?
|
| Attitude of Health Personnel | 3 | 2002 | 3839 | 0.030 |
Why?
|
| Young Adult | 2 | 2019 | 56350 | 0.030 |
Why?
|
| Certification | 1 | 1999 | 423 | 0.030 |
Why?
|
| Family | 2 | 2017 | 3144 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15056 | 0.030 |
Why?
|
| Personality Assessment | 2 | 2009 | 643 | 0.030 |
Why?
|
| Hypertension | 1 | 2012 | 8455 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1999 | 1548 | 0.020 |
Why?
|
| Meperidine | 1 | 1991 | 38 | 0.020 |
Why?
|
| Narcotic Antagonists | 1 | 2016 | 562 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 1995 | 634 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 1997 | 4929 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2016 | 1961 | 0.020 |
Why?
|
| Alprazolam | 1 | 1990 | 98 | 0.020 |
Why?
|
| Drug Interactions | 2 | 2012 | 1458 | 0.020 |
Why?
|
| Anthropometry | 1 | 2015 | 1350 | 0.020 |
Why?
|
| Trazodone | 1 | 1990 | 66 | 0.020 |
Why?
|
| Attitude to Health | 1 | 1998 | 2051 | 0.020 |
Why?
|
| Drug Eruptions | 1 | 2012 | 295 | 0.020 |
Why?
|
| Child Abuse | 1 | 1998 | 1030 | 0.020 |
Why?
|
| Dopamine | 1 | 1996 | 1589 | 0.020 |
Why?
|
| Lorazepam | 1 | 1989 | 145 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2012 | 469 | 0.020 |
Why?
|
| Psychomotor Agitation | 1 | 1990 | 288 | 0.020 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1990 | 434 | 0.020 |
Why?
|
| Catatonia | 1 | 1990 | 157 | 0.020 |
Why?
|
| Indicator Dilution Techniques | 1 | 2006 | 41 | 0.020 |
Why?
|
| Echinocandins | 1 | 2006 | 44 | 0.020 |
Why?
|
| Self-Injurious Behavior | 1 | 2012 | 462 | 0.020 |
Why?
|
| Animals | 1 | 2019 | 168561 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2006 | 75 | 0.020 |
Why?
|
| Amphotericin B | 1 | 2006 | 137 | 0.020 |
Why?
|
| Personality | 1 | 2009 | 548 | 0.020 |
Why?
|
| Health Status | 1 | 1998 | 4030 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 2006 | 401 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2009 | 7901 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1996 | 8297 | 0.010 |
Why?
|
| Erotica | 1 | 2002 | 22 | 0.010 |
Why?
|
| Sex Factors | 1 | 1995 | 10392 | 0.010 |
Why?
|
| Epilepsy | 1 | 1997 | 3301 | 0.010 |
Why?
|
| Outpatients | 1 | 2009 | 1483 | 0.010 |
Why?
|
| Triazoles | 1 | 2006 | 907 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 1871 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2009 | 6365 | 0.010 |
Why?
|
| Age Factors | 1 | 1995 | 18355 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 6474 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 1996 | 15530 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1999 | 623 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2372 | 0.010 |
Why?
|
| Specialty Boards | 1 | 1999 | 227 | 0.010 |
Why?
|
| Parkinson Disease | 1 | 1991 | 2774 | 0.010 |
Why?
|
| Amnesia | 1 | 1999 | 244 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 10943 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2006 | 2933 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 5979 | 0.010 |
Why?
|
| Cues | 1 | 1998 | 868 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 13921 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 16331 | 0.010 |
Why?
|
| Child | 2 | 1998 | 77478 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 9941 | 0.000 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2002 | 3649 | 0.000 |
Why?
|
| Clinical Competence | 1 | 2002 | 4681 | 0.000 |
Why?
|
| Referral and Consultation | 1 | 1998 | 3527 | 0.000 |
Why?
|
| Depression | 1 | 2002 | 7733 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 39004 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 19862 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1998 | 40955 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1998 | 53187 | 0.000 |
Why?
|